Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 53

Castle Biosciences Launches Next-Generation Sequencing Test DecisionDx-CMSeq for Cutaneous Melanoma

Posted by fidest press agency su giovedì, 31 maggio 2018

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-CMSeq test that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to cutaneous (skin) melanoma (CM). The DecisionDx-CMSeq NGS test will provide additional information to complement Castle Biosciences’ DecisionDx®-Melanoma gene expression profile (GEP) test that predicts individual risk of recurrence in patients with melanoma.The DecisionDx-CMSeq test evaluates DNA mutations in two genes known to be relevant to melanoma, BRAF and NRAS. The test can be ordered in conjunction with the DecisionDx-Melanoma GEP test or as a standalone request.“It is critical to understand as much as possible about a patient’s melanoma in order to individualize care,” said Federico A. Monzon, M.D., FCAP, Chief Medical Officer of Castle Biosciences. “The DecisionDx-Melanoma gene expression profile test is currently used to guide follow-up, surveillance and sentinel lymph node biopsy discussions based on metastatic risk. With the addition of mutational sequencing, we can provide actionable information for treatment options, including adjuvant therapy and clinical trials.”BRAF is the most commonly mutated gene in melanoma, with mutations found in approximately 40 to 50% of CM tumors. The DecisionDx-CMSeq test analyzes mutations in exon 15 of BRAF, where the most common and clinically actionable mutations occur. There are FDA-approved therapies for use in certain patients with particular BRAF mutations, as well as clinical trials underway evaluating new therapies.Approximately 20% of melanoma tumors harbor mutations in NRAS. The DecisionDx-CMSeq test identifies mutations affecting codons G12, G13 and Q61 of the NRAS gene. Patients with NRAS mutations are likely to be resistant to single-agent BRAF targeted therapy. There are several ongoing clinical trials evaluating compounds that target tumors with the NRAS mutation. Additional information about the genes in the DecisionDx-CMSeq test is available here on the website.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: